An estimated 24 million Americans will use these weight loss drugs by 2035, posing significant challenges as well as ...

Joey Gonzalez, global co-CEO of Barry’s, joins CNBC to discuss outlooks on fitness in the era of GLP-1 drugs, trends in gym ...

Losing weight by dieting (restricting energy) includes, along with fat loss, losing lean mass, about half of which is ...

Intuitively, it would seem that GLP-1 use for obesity would reduce overall medical costs despite the increase in drug ...

A nationwide study confirms GLP-1 RAs pose no short-term psychiatric risk, showing a negative association with suicidal ...

Kwame Raoul’s office sent cease and desist letters to five unnamed medical spas in the Chicago area that were allegedly ...

Whether they’re trying to initiate them or keep up with them, food manufacturers tend to roll with the latest trends. Remember the no-fat fad? It was great until consumers realized that some fat ...

The drugs were first approved to treat type 2 diabetes – and that's what the FDA said daily injections of liraglutide could ...

Seeking Alpha analyst Terry Chrisomalis regards Viking Therapeutics as the most attractive M&A candidate in 2025, bolstered ...

The United States Food and Drug Administration says the shortage of Eli Lilly’s Zepbound and Mounjaro drugs has been resolved ...

GLP-1, or Glucagon-like peptide-1, medications, similar to Ozemppic and Wegovy, are becoming more accessible, and while the drugs can help users shed a few pounds, they can come with some risks and ...